“As the field of DHT-enabled measures continues to mature, it was very illuminating and reassuring to hear from the biopharmaceutical industry, the technology sector, and academia about progress made in the field since the inception of DiMe and the publication of the V3 framework, which were fundamental to the field. We have heard each other’s stories, shared experiences, and developed resources that will help us move forward together and faster.”

– Elena Izmailova | Chief Scientific Officer, Koneksa Health